Tools


Home > News


news

RSS

09/12/2016

The Bioinformatics Barcelona Association presents the Research Program on Biomedical Informatics

You're still in time to sign up for the third visit of the "Get BIB", focused on this occasion on the Research Program on Biomedical Informatics (GRIB), joint research programme of the Hospital del Mar Medical Research Institute (IMIM) and the Department of Experimental and Health Sciences of UPF.

The presentation will take place on Monday 12 December from 10:00 to 12:00h at Ramón y Cajal room of Barcelona Biomedical Research Park (Doctor Aiguader, 88, Barcelona), and since seating is limited, it needs your attendance confirmation by sending an email to comunicacio@bioinformaticsbarcelona.eu

More information

High levels of CPEB4 expression in human melanoma. The image shows a melanoma biopsy stained for CPEB4 factor (in red) and one of its target genes (RAB27, in green). /CNIO

28/11/2016

A protein that defines the melanoma blueprint

Identified a new factor essential for the development of these aggressive tumours. This protein helps to define aspects that distinguish melanoma from other types of cancer

A recent publication at Nature Communications identified a new factor essential for the development of these aggressive tumours: the CPEB4, a protein that is crucial for melanoma cell survival. This protein helps to define aspects that distinguish melanoma from other types of cancer. 

The Computational RNA Biology group of GRIB led by Eduardo Eyras has participated on this study  headed by Marisol Soengas from the Spanish National Cancer Research Centre (CNIO), senior author of this paper, an expert in researching the "identity" of melanomas.

Reference article: Lineage-specific roles of the cytoplasmic polyadenylation factor CPEB4 in the regulation of oncogenic drivers in melanoma. Eva Pérez-Guijarro, Panagiotis Karras, Metehan Cifdaloz, Raúl Martínez-Herranz, Estela Cañón, Osvaldo Graña, Celia Horcajada, Direna Alonso-Curbelo, Tonantzin G. Calvo, Gonzalo Gomez, Nicolas Bellora, Erica Riveiro-Falkenbach, Pablo Otiz-Romero, José Luis Rodríguez-Peralto, Lorena Maestre, Giovanna Roncador, Juan C de Agustín Asensio, Colin R. Goding, Eduardo Eyras, Diego Megías, Raúl Méndez and María S. Soengas. Nature Communications (2016). DOI: http://dx.doi.org/10.1038/NCOMMS13418

More information

Befree

25/11/2016

Thesis defence of Àlex Bravo Serrano: "BeFree: a text mining system for the extraction of biomedical information from the literature"

Next Monday, 28th of November at 11:00, Àlex Bravo Serrano, member of the Integrative Biomedical Informatics group of GRIB will defense his thesis "BeFree: a text mining system for the extraction of biomedical information from the literature" at Josep Marull room of the Universitat Pompeu Fabra.

More information

18/11/2016

Thesis defence of José Carlos Gómez Tamayo: "Development and application of computational techniques to drug discovery and structure-function relationships"

Next Friday, 25th of November at 11:30,  José Carlos Gómez Tamayo, member of the PharmacoInformatics group of GRIB will defense his thesis "Development and application of computational techniques to drug discovery and structure-function relationships" at PRBB Auditorium.

More information

3/10/2016

​Project EU-ToxRisk and US Initiative Tox21 new collaboration

The EU-ToxRisk project and the Toxicology in the 21st Century (Tox21) initiative in the US have agreed to collaborate on efforts to reduce the use of animals and achieve more efficient chemical safety assesments. A total of 28 representatives from both projects gathered in a workshop held in Mainz (Germany) on the 12th-14th September 2016 to initiate collaboration across areas of mutual interest within the field of risk assessment.

Two groups of GRIB participate in the EU-ToxRisk project coordinating the application of computational methods: the PharmacoInformatics group led by Manuel Pastor and the Integrative Bioinformatics group led by Ferran Sanz, and therefore will play a major role in this collaboration. In particular, the GRIB will participate in the joint development and validation of core methodologies for hazard and risk assessment, as read-across, quantitative AOP and similarity metrics.

You can find further information in the EU-ToxRisk-Tox21 joint Press Release (in english) and the translation into catalan and spanish at the UPF website.

More information

22/09/2016

3rd Workshop on High-Throughput Molecular Dynamics (HTMD) in Barcelona

The event will take place on 10th & 11th of November at the Barcelona Biomedical Research Park (PRBB) in Barcelona. Registration closes the 30th of September.

The aim of this workshop is to learn the latest developments of high-throughput molecular dynamics simulations with practical lectures and real data and to give scientists the opportunity to exchange their experiences. Hands-on session and training will be given using HTMD a powerful programmable environment to prepare, handle, simulate and analyze molecular simulations, and efficient GPU-based MD simulations, and standard protocols to execute numerical experiments. There will be at the end of the workshop a session on applying what you have learned on your data/proteins.

This workshop is a great opportunity for industrial partners to get an overview of the state-of-the-art in molecular simulations for medicinal chemistry and drug design.

Acellera is a technology spin off of the GRIB, focused on delivering services and solutions to companies and academic institutions on computing intensive, mission-critical applications. By exploiting heavily optimized molecular simulations and the outstanding computational capabilities of new accelerator processors, we help to achieve otherwise unreachable results using current standard technology.

More information

5/10/2016

Computational Genomics group is now Computational RNA Biology group

In its 10th anniversary, the GRIB group led by Eduardo Eyras changes its name to "Computational RNA Biology group" to reflect the contributions by the group during these past years and its well-recognized expertise in the study of different aspects of RNA using computational methods, including RNA structure, RNA splicing regulation, chromatin and RNA, alternative splicing, non-coding RNAs, as well as the relevance of RNA biology in cancer. You can read more about the activities of the group in this web and also at the new group website: http://comprna.upf.edu/

More information

26/10/2016

Una eina web per ajudar a detectar mutacions cancerígenes

Els correctes tractament i diagnòstic del càncer depenen cada vegada més de l'anàlisi genètica dels pacients. En aquesta anàlisi es busquen alteracions en l'ADN del tumor, anomenades mutacions, que puguin tenir un valor diagnòstic, pronòstic o terapèutic per a la malaltia. Per poder identificar aquestes mutacions s'ha de seqüenciar l'ADN del tumor, ja sigui abastant tot el seu genoma, el seu exoma (és a dir, la part funcional del genoma) o bé només certs gens o regions gèniques, que s'inclouen en panells. La seqüenciació mitjançant panells presenta avantatges respecte a la seqüenciació de tot el genoma o exoma perquè, a més de comptar amb un coeficient de cost / benefici millor, els panells detecten menys falsos positius gràcies a la seva major sensibilitat.

El grup de Genòmica Biomèdica del GRIB (IMIM-UPF), ha creat OncoPaD, la primera eina web oberta a tota la comunitat científica per dissenyar panells de seqüenciació per càncer que tenen en compte el coneixement previ rellevant al tipus de tumor d'interès i el cost/benefici estimat pot ser ajustat pels investigadors. Segons els autors de l'estudi "mitjançant una interfície senzilla i intuïtiva, OncoPaD identifica quins gens o regions són els millors candidats per al disseny d'un panell específic, basant-se en l'associació coneguda dels gens amb mecanismes de desenvolupament del càncer o resposta a fàrmacs contra aquest i maximitzant el seu coeficient de cost /benefici" i també "a causa de la important necessitat que cobreix i la facilitat de la seva utilització, OncoPaD hauria d'esdevenir una eina d'ús freqüent per part d'investigadors clínics i translacionals d'oncologia". L'estudi ha estat publicat a la revista Genome Medicine.

More information

visual summary of the research

16/09/2016

Cellular stress activates an important anti-cancer protein

Researchers at UPF have discovered that the RB protein, responsible for stopping cell proliferation and therefore preventing tumor formation, is activated under cellular stress. The Structural Bioinformatics group of GRIB led by Baldo Oliva has participated on this work led by Eulàlia de Nadal and Francesc Posas, leaders of the research group on Cell Signaling of the UPF.

The study has been published in the journal Molecular Cell and shows that RB is also important to stop cell progression in response to cellular stress. Under these conditions, the brake is essential for cell survival. A very remarkable fact is that this new mechanism predominates over others that normally regulate the activity of RB. Therefore, the external activation of this mechanism could be used to block cell division.

As Francesc Posas, co-leader of the study says, "this discovery may be relevant in cancer biology because RB is a key protein in cell proliferation and many types of tumor coincide on the inactivation of this protein. If we get to reverse this inhibition, we could stop proliferation."

More information

6/9/2016

Researchers of GRIB participate in a crowdsourced assessment of the treatment response in rheumatoid arthritis

The researchers of the Structural Bioinformatics group of GRIB (IMIM-UPF), led by Baldo Oliva, recently participated in the Reumatoid Arthritis (RA) Responder challenge in which participants had to identify individuals most likely to fail response to RA therapies. The study was awarded with the first prize, it was presented at the Seventh Annual RECOMB/ ISCB Conference and has been eventually published at the Nature Communications magazine. 

Rheumatoid Arthritis (RA) is a debilitating autoimmune disease that affects millions world-wide and manifests through proinflammatory joint damage. Reducing inflammation is essential to prevent long-term deleterious effects in RA. 

Article reference: Sieberts SK, Zhu F, García-García J, Stahl E, Pratap A, Pandey G, Pappas D, Aguilar DAnton B, Bonet J, Eksi R,Fornés O, Guney E, Li H, Marín MA, Panwar B, Planas-Iglesias J, Poglayen D, Cui J, Falcao AO et al (including Oliva B). Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nature Communications, 2016; 7: 12460. DOI: doi:10.1038/ncomms12460.

More information



Site Information